Sarver Vrooman Wealth Advisors’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$91.4K Hold
613
– – 0.05% 36
2026
Q2
$78.9K Hold
613
– – 0.05% 37
2026
Q1
$85.4K Hold
613
– – 0.05% 33
2025
Q4
$75.2K Sell
613
-16
-3% -$1.94K 0.05% 33
2025
Q3
$69.8K Hold
629
– – 0.04% 48
2025
Q2
$69.7K Hold
629
– – 0.05% 44
2025
Q1
$70.5K Buy
+629
New +$64.9K 0.05% 59

Other funds holding GILD

Sarver Vrooman Wealth Advisors's GILD Position: Q3 2026 in Review

Sarver Vrooman Wealth Advisors held its Gilead Sciences (GILD) position steady in Q3 2026 at 613 shares worth $91.4K. The position accounts for 0.05% of the portfolio, ranked #36.

Sarver Vrooman Wealth Advisors first reported a position in GILD in Q1 2025 and has held it in 7 quarters since. 302 funds tracked by Wall St. Rank hold GILD as of Q3 2026.

  • Sarver Vrooman Wealth Advisors held 613 shares of Gilead Sciences worth $91.4K as of Q3 2026.
  • Sarver Vrooman Wealth Advisors left its Gilead Sciences share count unchanged in Q3 2026.
  • Gilead Sciences made up 0.05% of Sarver Vrooman Wealth Advisors's portfolio in Q3 2026, its #36 holding.
  • Sarver Vrooman Wealth Advisors first reported a position in Gilead Sciences in Q1 2025 and has held it in 7 quarters since.
  • 302 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2026.

Based on Sarver Vrooman Wealth Advisors's 13F filing for Q3 2026, filed 1 Oct 2026.